194 related articles for article (PubMed ID: 28740382)
1. Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro.
Wang C; Zhu W; Wang BZ
Int J Nanomedicine; 2017; 12():4747-4762. PubMed ID: 28740382
[TBL] [Abstract][Full Text] [Related]
2. Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity.
Wang C; Zhu W; Luo Y; Wang BZ
Nanomedicine; 2018 Jun; 14(4):1349-1360. PubMed ID: 29649593
[TBL] [Abstract][Full Text] [Related]
3. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains.
Dong C; Wang Y; Gonzalez GX; Ma Y; Song Y; Wang S; Kang SM; Compans RW; Wang BZ
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941704
[TBL] [Abstract][Full Text] [Related]
4. Enhanced humoural and cellular immune responses to influenza H7N9 antigen HA1-2 fused with flagellin in chickens.
Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
BMC Vet Res; 2017 Jun; 13(1):190. PubMed ID: 28637471
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant flagellin in oil-in-water emulsions enhances hemagglutinin-specific mucosal IgA production and IL-17 secreting T cells against H5N1 avian influenza virus infection.
Lai CH; Tang N; Jan JT; Huang MH; Lu CY; Chiang BL; Huang LM; Wu SC
Vaccine; 2015 Aug; 33(35):4321-9. PubMed ID: 25858857
[TBL] [Abstract][Full Text] [Related]
6. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
7. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.
Deng L; Kim JR; Chang TZ; Zhang H; Mohan T; Champion JA; Wang BZ
Virology; 2017 Sep; 509():82-89. PubMed ID: 28622575
[TBL] [Abstract][Full Text] [Related]
8. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
[TBL] [Abstract][Full Text] [Related]
9. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
[TBL] [Abstract][Full Text] [Related]
10. Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses.
Wang Y; Li S; Dong C; Ma Y; Song Y; Zhu W; Kim J; Deng L; Denning TL; Kang SM; Prausnitz MR; Wang BZ
ACS Appl Bio Mater; 2021 Jun; 4(6):4953-4961. PubMed ID: 34179728
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
12. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.
Wang BZ; Gill HS; Kang SM; Wang L; Wang YC; Vassilieva EV; Compans RW
Clin Vaccine Immunol; 2012 Aug; 19(8):1119-25. PubMed ID: 22647270
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.
Weldon WC; Wang BZ; Martin MP; Koutsonanos DG; Skountzou I; Compans RW
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824188
[TBL] [Abstract][Full Text] [Related]
14. Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice.
Dong C; Wang Y; Zhu W; Ma Y; Kim J; Wei L; Gonzalez GX; Wang BZ
ACS Appl Mater Interfaces; 2022 Feb; 14(5):6331-6342. PubMed ID: 35084819
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
16. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus.
Lei H; Peng X; Shu H; Zhao D
J Med Virol; 2015 Jan; 87(1):39-44. PubMed ID: 24861477
[TBL] [Abstract][Full Text] [Related]
18. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.
Wang BZ; Xu R; Quan FS; Kang SM; Wang L; Compans RW
PLoS One; 2010 Nov; 5(11):e13972. PubMed ID: 21124769
[TBL] [Abstract][Full Text] [Related]
19. Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge.
Mallajosyula JK; Hiatt E; Hume S; Johnson A; Jeevan T; Chikwamba R; Pogue GP; Bratcher B; Haydon H; Webby RJ; McCormick AA
Hum Vaccin Immunother; 2014; 10(3):586-95. PubMed ID: 24378714
[TBL] [Abstract][Full Text] [Related]
20. Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin.
Wang W; Alvarado-Facundo E; Vassell R; Collins L; Colombo RE; Ganesan A; Geaney C; Hrncir D; Lalani T; Markelz AE; Maves RC; McClenathan B; Mende K; Richard SA; Schofield C; Seshadri S; Spooner C; Utz GC; Warkentien TE; Levine M; Coles CL; Burgess TH; Eichelberger M; Weiss CD
Clin Infect Dis; 2021 Dec; 73(11):e4312-e4320. PubMed ID: 32898271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
